Questions around industry compliance with postmarketing requirements in the Pediatric Research Equity Act (PREA), and whether FDA has sufficient enforcement tools and incentives to ensure studies are timely completed, could be up for discussion in the next reauthorization of the Prescription Drug User Fee Act.
A recent Health and Human Services' Office of Inspector General report suggested PREA studies represented a high percentage of FDA...







